# The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model

## TL;DR

This study shows that Edaravone can protect the heart from kidney injury-induced damage in rats by boosting antioxidant activity.

## Contribution

The novel finding is Edaravone's protective effect on cardiac tissues in a kidney ischemia-reperfusion model through enhanced antioxidant enzymes.

## Key findings

- Edaravone significantly increased glutathione peroxidase, catalase, and superoxide dismutase activity in cardiac tissues.
- The drug also elevated glutathione and total antioxidant capacity in the heart compared to the ischemia-reperfusion group.
- Edaravone showed a safe profile with increased antioxidant capacity in the heart even without kidney injury.

## Abstract

Acute kidney injury (AKI) is a common clinical occurrence causing high mortality and morbidity. In acute renocardiac syndrome, AKI leads to acute cardiac injury or/and dysfunction. This study aimed to investigate the antioxidative effects of Edaravone on cardiac tissues following the induction of renal ischemia-reperfusion injury (IRI) in rats.

Twenty-four male Wistar rats were randomly divided into four groups: IR+Edaravone, Edaravone, IR, and Sham groups (six rats per group). Non-traumatic clamps were used to stop the artery and vein blood flow of the left kidney in rats of the IR groups for 45 minutes. Thirty minutes before ischemia induction, Edaravone (3 mg/kg) was injected intraperitoneally in the IR+Edaravone group. Cardiac samples were subjected to biochemical analyses.

The Results showed a significant increase in the enzymatic activity of glutathione peroxidase (P=0.01), catalase (P=0.03), and superoxide dismutase (P=0.02), and the levels of glutathione (P=0.012), and total antioxidant capacity (P<0.001) in the IR+Edaravone group in comparison to the IR group. Moreover, the total antioxidant capacity of the heart was increased in the Edaravone group compared to the control and IR groups (P<0.001), indicating the safety of the drug.

The results can reveal important insights into the protective effects of Edaravone against acute renocardiac syndrome.